Press Release Advanced Bionics Announces FDA Approval of Expanded Cochlear Implant Inclusion Criteria for Patients with Single-Sided Deafness and Asymmetric Hearing Loss Advanced Bionics · Jul 28
Press Release The 20-Minute Payroll Myth: How Hemiton Global Eliminates the 11–13 Days of Hidden Payroll Work Issuewire · Jul 28
Press Release Mission Inbox Acquires CeyMail to Fix Spam at the Source as AI Reshapes the Inbox Mission Inbox · Jul 28
Press Release Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth Nasus Pharma, Ltd. · Jul 28
Press Release PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc. PMGC Holdings Inc. · Jul 28
Press Release Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer Kazia Therapeutics Ltd · Jul 28
Press Release ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform ZenaTech Inc. · Jul 28
Press Release Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) Dyne Therapeutics, Inc. · Jul 28
Press Release VR Confirms New IP and Conductivity Anomalies on its Bonita Property Porphyry Copper-Gold Project in Nevada VR Resources Ltd. · Jul 28
Press Release Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus Atea Pharmaceuticals, Inc. · Jul 28
Press Release Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients Lungpacer Medical USA Inc. · Jul 28
Press Release Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration Grace Therapeutics, Inc. · Jul 28
Press Release Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML Cullinan Therapeutics, Inc. · Jul 28